Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- Conditions
- Diffuse Large Cell LymphomaNon-Hodgkin LymphomaBurkitt LymphomaPlasmablastic LymphomaB-Cell Neoplasm
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT05389423
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors
- Conditions
- KRAS G12V Mutant Advanced Epithelial Cancers
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Providence Health & Services
- Registration Number
- NCT05389514
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 20
- Registration Number
- NCT05385705
- Locations
- 🇪🇸
Vall d'Hebron Hospital, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
- Conditions
- Medulloblastoma
- Interventions
- Drug: CisplatinDrug: CyclophosphamideDrug: LomustineDrug: MesnaOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: Sodium ThiosulfateOther: Survey AdministrationDrug: Vincristine
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 225
- Registration Number
- NCT05382338
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Kaiser Permanente-Oakland, Oakland, California, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
......SMARTEST Trial......
- Conditions
- Mesothelioma, Malignant
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 30
- Registration Number
- NCT05380713
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
- Conditions
- B-cell LymphomaB-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 24
- Registration Number
- NCT05379647
- Locations
- 🇨🇳
The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 230
- Registration Number
- NCT05371093
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebrón, Barcelona, Spain
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸Instituto Catalan de Oncologia - Hospital Duran i Reynolds (ICO L'Hospitalet), Barcelona, Spain
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
- Conditions
- Glioma, Malignant
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Epitopoietic Research Corporation
- Target Recruit Count
- 28
- Registration Number
- NCT05366062
- Locations
- 🇹🇭
Bumrungrad International Hospital, Bangkok, Vadhana, Thailand
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaPrimary MyelofibrosisMyelodysplastic SyndromeMyeloproliferative NeoplasmSecondary Myelofibrosis
- Interventions
- Drug: CyclophosphamideDrug: ItacitinibProcedure: Peripheral Blood Stem Cell TransplantationOther: Quality-of-Life AssessmentDrug: Tacrolimus
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT05364762
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Refractory Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRefractory Primary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Drug: CyclophosphamideDrug: FludarabineBiological: Lisocabtagene MaraleucelDrug: Polymer-conjugated IL-15 Receptor Agonist NKTR-255Procedure: X-Ray ImagingProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Lumbar PunctureProcedure: Computed TomographyProcedure: Positron Emission TomographyProcedure: Biospecimen CollectionProcedure: Biopsy
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05359211
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.